Drug intelligence / Profile preview

Gylden Chikungunya vaccine

Development stage: Preclinical
Lead developer: Gylden Pharma
Modality: Vaccines & Immunotherapeutics, Peptides
Administration: Intradermal, Intramuscular

Overview

The Gylden Chikungunya vaccine is a preclinical-stage synthetic T cell-priming vaccine being developed by Gylden Pharma for the prevention of Chikungunya virus (CHIKV) infection. Utilizing a proprietary synthetic platform, the vaccine is designed to elicit a robust and specific T-cell mediated immune response, rather than relying solely on the induction of neutralizing antibodies. This approach aims to provide broad and durable protection against the virus by targeting conserved viral epitopes. As of early 2024, the vaccine remains in the preclinical phase of development.

Other names: Gylden Pharma Chikungunya vaccineSynthetic T cell-priming Chikungunya vaccine

Targets

Chikungunya virus-specific CD8+ T cell receptorMHC I (MHC class I})

Beyond the preview

Go deeper on Gylden Chikungunya vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gylden Chikungunya vaccine.